Today: 11 June 2026
BNAI stock doubles as Brand Engagement Network lands AI pharma deal, eyes recurring fees
30 December 2025
2 mins read

BNAI stock doubles as Brand Engagement Network lands AI pharma deal, eyes recurring fees

NEW YORK, December 29, 2025, 23:20 ET — Market closed

  • Brand Engagement Network shares closed up 108.8% on Monday after disclosing a pharma-focused AI engagement contract.
  • The company said it expects $250,000 in Q4 development revenue and anticipates monthly license fees in Q1 2026.
  • Traders are watching for deployment timing, follow-on work and the stock’s ability to hold key technical levels.

Brand Engagement Network, Inc shares more than doubled on Monday after the company disclosed a project agreement to develop a custom AI engagement tool tied to an established prescription drug for a top-10 global pharmaceutical client. The company said it expects $250,000 in fourth-quarter development revenue and anticipates monthly license fees starting in the first quarter of 2026; the stock closed up 108.8% at $2.51.

The agreement offers a near-term revenue catalyst for a thinly traded AI microcap trying to prove it can turn pilot work into repeatable contracts and recurring software fees. The timing matters with the quarter winding down, when investors focus on what revenue is likely to be recognized and what cash is available to fund operations.

In its latest quarterly report, BEN said its liquidity position raised substantial doubt about its ability to continue as a going concern, with cash and cash equivalents of about $102,715 at Sept. 30. The filing showed revenue of $60,120 for the quarter and $75,120 for the first nine months.

BNAI traded between $1.77 and $2.91 on Monday, with volume swelling to about 148.6 million shares versus roughly 149,000 shares on Friday, according to market data.

Statements of Work — common contract add-ons — typically spell out the specific deliverables, timelines and acceptance criteria for each phase of a project. License fees are recurring payments for continued use of software once a tool is implemented.

Acting Chief Executive Officer Tyler Luck said the deal “reflects BEN’s progression in healthcare,” calling the company’s AI “trusted, secured, and efficient.” The press release also pointed to the company’s broader push into healthcare initiatives, including work tied to Latin America. PR Newswire

Brand Engagement Network develops conversational AI software and human-like AI avatars aimed at customer engagement, according to the company’s investor materials.

Investors will be looking for evidence the initial development work converts into recurring fees and expands into additional Statements of Work or similar projects, particularly if the company provides more detail when the solution is formally released.

Before next session, chart watchers will be focused on whether BNAI can hold above the $2.50 area after Monday’s spike. The day’s $1.77 low marks a near-term support level, with the $2.91 intraday high a nearby ceiling if momentum resumes.

A clear date for the company’s next earnings update was not listed on Nasdaq’s earnings page late Monday, leaving traders to rely on company disclosures and future filings for the next scheduled catalyst.

In the broader market on Tuesday, investors will track U.S. data including the S&P Case-Shiller home price index and the Chicago PMI, with thin year-end liquidity often amplifying moves in smaller, lower-priced stocks.

Stock Market Today

  • How to Invest Indirectly in SpaceX Before IPO Through ETFs
    June 11, 2026, 10:46 AM EDT. Investors can gain indirect exposure to SpaceX ahead of its IPO via ETFs like ERShares Private-Public Crossover ETF (XOVR) and AGIX. These funds use special purpose vehicles (SPVs)-legal entities holding SpaceX shares-to navigate SEC rules allowing up to 15% allocation in illiquid private companies. XOVR holds about 13.2% exposure to SpaceX through SPVs, while AGIX combines SPV investments with a small direct stake. Investors should note these ETFs are thematic portfolios with broad tech focuses and relatively high expense ratios. Direct public investment remains available only after SpaceX's Nasdaq debut at ticker SPCX on June 12, priced around $135, targeting a $1.75-$2 trillion valuation.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers
Previous Story

AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers

Nvidia stock dips after AI21 Labs talk report as NVDA investors size up Intel stake
Next Story

Nvidia stock dips after AI21 Labs talk report as NVDA investors size up Intel stake

Go toTop